BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ruzaltatug rezetecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ruzaltatug rezetecan\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06671379-2181@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ruzaltatug rezetecan: Phase 3 readout est. (NCT06671379)
DESCRIPTION:Ruzaltatug rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-muta
 ted\, Advanced or Metastatic NSCLC\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruzaltatug-rez
 etecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06671379
URL:https://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05114759-2181@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ruzaltatug rezetecan: Phase 1 readout est. (NCT05114759)
DESCRIPTION:Ruzaltatug rezetecan\, phase 1.\nStudy: A Phase I Clinical Stud
 y of SHR-A2009 for Injection in Patients With Advanced Solid Tumors\nEstim
 ated primary completion: 30 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05114759
URL:https://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07414953-2181@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ruzaltatug rezetecan: Phase 1 readout est. (NCT07414953)
DESCRIPTION:Ruzaltatug rezetecan\, phase 1\, Non-Small Cell Lung Cancer.\nS
 tudy: A Phase Ib Study of HS-10504 Combined Therapy in NSCLC\nEstimated pr
 imary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ruzaltatug-rezetecan#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07414953
URL:https://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07863167-2181@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Ruzaltatug rezetecan: Phase 2 readout est. (NCT07863167)
DESCRIPTION:Ruzaltatug rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: An Open\, Multicenter Phase II Clinical Trial of SHR-A2009 Combined 
 With Other Anti-tumor Therapies for Perioperative Treatment of Resectable 
 Non-small Cell Lung Cancer.\nEstimated primary completion: 30 December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ruzaltatug-rezetec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7863167
URL:https://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895992-2181@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Ruzaltatug rezetecan: Phase 3 readout est. (NCT07895992)
DESCRIPTION:Ruzaltatug rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Adva
 nced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized 
 Controlled\, Open\, Multicenter Phase III Study\nEstimated primary complet
 ion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ruzaltatug-rezetecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07895992
URL:https://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06474455-2181@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Ruzaltatug rezetecan: Phase 1/2 readout est. (NCT06474455)
DESCRIPTION:Ruzaltatug rezetecan\, phase 1/2.\nStudy: A Phase IB/II Clinica
 l Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies
  in Patients With Advanced Solid Tumors\nEstimated primary completion: Jun
 e 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruzaltatug-re
 zetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06474455
URL:https://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07183189-2181@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Ruzaltatug rezetecan: Phase 3 readout est. (NCT07183189)
DESCRIPTION:Ruzaltatug rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib 
 for First-line Treatment in EGFR-mutated\, Advanced or Metastatic NSCLC\nE
 stimated primary completion: November 2032. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07183189
URL:https://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
